Finance

Beta
Lists
FULC:NASDAQ
Fulcrum Therapeutics Inc
$3.80
+0.93%
(+0.035) 1D
Jun 23, 1:28:13 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for FULC...
Open
$3.69
High
$3.89
Low
$3.69
Mkt. cap
253.54M
Avg. vol.
3.32M
Volume
1.07M
52-wk high
$15.74
52-wk low
$2.83
EPS
-$1.15
Beta
2.93
Shares outstanding
66.63M
No. of employees
55
Open
$3.69
High
$3.89
Low
$3.69
Mkt. cap
253.54M
Avg. vol.
3.32M
Volume
1.07M
52-wk high
$15.74
52-wk low
$2.83
EPS
-$1.15
Beta
2.93
Shares outstanding
66.63M
No. of employees
55
News stories
From sources across the web
About Fulcrum Therapeutics Inc
CEO-
Employees55
Founded2015
Headquarters-
SectorPharmaceutical industry
Websitefulcrumtx.com
Analyst Ratings
Based on 9 analysts giving stock ratings to FULC in the past 3 months
Hold
Buy
1
Hold
5
Sell
3
12 month forecast
Based on 9 Wall Street analysts offering 12 month price targets for FULC in the last 3 months.
Highest
Current $3.80
$15.00 (+294.22%)
Average
$4.88 (+28.25%)
Lowest
$3.00 (-21.16%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Anupam Rama
J.P. Morgan
Sell
Downgraded
-
-
06/02/2026
Tazeen Ahmad
Bank of America Securities
Sell
Maintained
$3.00
-21.2%
06/02/2026
Andrew Fein
H.C. Wainwright
Hold
Downgraded
$3.00
-21.2%
06/02/2026
Joseph Schwartz
Leerink Partners
Hold
Downgraded
$4.00
+5.1%
06/02/2026
Gregory Renza
Truist Financial
Hold
Downgraded
$4.00
+5.1%
06/02/2026
Edward Tenthoff
Piper Sandler
Sell
Downgraded
$3.00
-21.2%
06/02/2026
James Condulis
Stifel Nicolaus
Hold
Downgraded
$3.00
-21.2%
06/02/2026
Luca Issi
RBC Capital
Hold
Maintained
$4.00
+5.1%
06/02/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$15.00
+294.2%
04/28/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$24.00
+530.7%
03/19/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
12.99M
14.30M
15.42M
14.08M
Cost of revenue
12.99M
14.30M
15.42M
14.08M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.83M
7.56M
7.28M
8.10M
Operating expense
6.83M
7.56M
7.28M
8.10M
Total operating expenses
19.82M
21.86M
22.69M
22.19M
Operating income
-19.82M
-21.86M
-22.69M
-22.19M
Other non operating income
-
-
-
-
EBT including unusual items
-17.30M
-19.60M
-20.33M
-18.89M
EBT excluding unusual items
-17.30M
-19.60M
-20.33M
-18.89M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-17.30M
-19.60M
-20.33M
-18.89M
Net profit margin
-
-
-
-
Earnings per share
-0.28
-0.31
-0.31
-0.25
Interest and investment income
2.52M
2.26M
2.36M
3.30M
Interest expense
-
-
-
-
Net interest expenses
2.52M
2.26M
2.36M
3.30M
Depreciation and amortization charges
-
-
-
-
EBITDA
-19.47M
-21.51M
-22.35M
-21.85M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer